Search results
This Drug Candidate Could Be a Winner for Bristol Myers
Motley Fool· 11 months agoLast month, Bristol Myers Squibb (NYSE: BMY) shared that its locally advanced or metastatic...
Bristol Myers to acquire brain drug developer Karuna for $14B
BioPharma Dive via Yahoo Finance· 4 months agoThe deal would hand Bristol Myers, which is reprioritizing neuroscience research, an experimental...
US FDA approves Bristol-Myers' lung cancer drug
Reuters via Yahoo News· 6 months agoThe drug, to be sold under the brand name Augtyro, is set to compete in a crowded market for lung cancer treatments that includes Bristol Myers' other...
Bristol Myers says KRAS drug succeeds in key trial
BioPharma Dive via Yahoo Finance· 1 month agoConfirmatory results for Krazati, which Bristol Myers acquired via its buyout of Mirati, could help the drug win full approval while Amgen has been set...
Bristol Myers wins dismissal of a $6.4 billion lawsuit over cancer drug delay
Reuters via Yahoo News· 1 year agoNEW YORK (Reuters) -A U.S. judge on Wednesday dismissed a lawsuit accusing Bristol Myers Squibb Co...
A Patent Cliff Is Coming For Bristol Myers — Can Billions In New Products Fill The Gap?
Investor's Business Daily· 1 year agoIt's a new day at Bristol Myers Squibb, according to a company executive. But BMY stock remains...
Bristol Myers pours $100M into RNA drugs for cardiovascular diseases
BioPharma Dive via Yahoo Finance· 5 months agoBristol Myers Squibb has agreed to spend at least $100 million to expand a partnership aimed at...
US FDA allows J&J, Bristol Myers cell therapies as early cancer treatments (April 5)
Reuters via AOL· 4 weeks agoThe U.S. Food and Drug Administration has allowed the cell therapies of Johnson & Johnson and...
Bristol-Myers Squibb to acquire Mirati in up to $5.8 billion deal
Reuters via AOL· 7 months ago(Reuters) -Bristol-Myers Squibb on Sunday said it will acquire cancer drugmaker Mirati Therapeutics...
FDA approves new Bristol Myers drug for lung cancer
BioPharma Dive via Yahoo Finance· 6 months agoAcquired via a $4 billion biotech buyout, Augtyro is one of an array of new products the pharma hopes will offset patent expirations for current top...
